Verteporfin fluorescence in antineoplastic-treated pancreatic cancer cells found concentrated in mitochondria

Figure 2 Proliferation of pancreatic cancer cells after incubation with different drugs. A and B: Proliferation of AsPC-1 cells (A) and BxPC-3 cells (B) after incubation with different concentrations of doxorubicin (nil, 0.2, 0.6, 0.8, 1.0, 1.2, 1.4 μmol/L) for 24 h and 48 h; C and D: Proliferation of AsPC-1 cells (C) and BxPC-3 cells (D) after incubation with different concentrations of gemcitabine (nil, 1.25, 2.5, 5, 10, 20, 30, 40, 50, 60, 70 μmol/L) for 3 h, 6 h, 12 h, 24 h, 48 h and 72 h; E and F: Proliferative viability of AsPC-1 cells (E) and BxPC-3 cells (F) after incubation with different concentrations of sirolimus (0 nmol/L, 1 nmol/L, 2 nmol/L, 3 nmol/L, 4 nmol/L, 5 nmol/L, 6 nmol/L, 7 nmol/L, 8 nmol/L, 9 nmol/L, 10 nmol/L) for 24 h, 48 h and 72 h; G and H: Proliferative viability of AsPC-1 cells (G) and BxPC-3 cells (H) after incubation with different concentrations of cetuximab (nil, 20, 40, 60, 80, and 100 μg/mL) for 24, 48 and 72 h; preformed in triplicate.